Pfizer’s CEO IanRead is resisting investor pressure to mastermind the next pharma mega-merger, saying that the company will be best served by investing in its drug pipeline. As the company has ...
Once a top-performing stock thanks to its role in developing the first Covid-19 vaccine, Pfizer has seen its share price drop by nearly half from its 2021 peak.
While Pfizer has made a number of acquisitions, its biggest bet is on Seagen. Pfizer wants this to be a transformative acquisition, and it projects Seagen to contribute $10 billion in sales by 2030.
The tweets were some of the most feral we've seen, but of course, DPR Ian had some fun with it. We counted, and by the end, his knee slapping and "goodness" reactions were at 16 and 15 ...